Riskpilot← Back to searchSign inGet full accessLEKAPHARM A/S
A/SActiveCVR 32945945Industrivej 8Wholesale of other food · NACE 4638Est. 20104 employees
Revenue 2024
DKK 6,2M
+79% vs 2023
EBITDA margin
56.9%
+269% vs 2023
Equity ratio
30.3%
Financial strength
Net profit 2024
DKK 2,1M
+341% vs 2023
| Revenue | DKK 6,2M | +79% |
| EBITDA | DKK 3,5M | +269% |
| Net profit | DKK 2,1M | +341% |
| Total assets | DKK 18M | +30% |
| Equity | DKK 5,5M | -15% |
| Employees | 4 | — |
Legal name
LEKAPHARM A/S
CVR number
32945945
Legal form
Aktieselskab
NACE code
4638 · Wholesale of other food
Founded
4. juni 2010
Share capital
DKK 500.000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af samlede bestyrelse eller af én direktør alene.
Company purpose
Selskabets formål er at drive virksomhed med produktion, ompakning og salg af kosttilskud samt dermed beslægtet virksomhed.
Address
Industrivej 8
Phone
+4562272793
Email
lekapharm@mail.tele.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.889 | 4.482 | 5.218 | 5.260 | 6.705 | 5.480 | 3.916 | 3.273 | 3.563 | 4.218 | 2.968 | 3.450 | 6.179 |
| Staff expenses | -2.115 | -2.079 | -2.063 | -2.373 | -2.198 | -1.995 | -1.922 | -1.930 | -2.341 | -3.073 | -2.542 | -2.498 | -2.663 |
| EBITDA | 777 | 2.403 | 3.155 | 2.856 | 4.508 | 3.485 | 1.994 | 1.343 | 1.089 | 1.116 | 426 | 952 | 3.515 |
| Depreciation & amort. | -0 | -1.068 | -1.100 | -477 | -280 | -292 | -289 | -322 | -397 | -299 | -363 | -330 | -280 |
| EBIT | 777 | 1.335 | 2.054 | 2.379 | 4.228 | 3.193 | 1.704 | 1.021 | 692 | 817 | 63 | 621 | 3.235 |
| Net financials | 29 | 59 | 70 | 79 | -74 | -124 | -243 | -208 | -126 | -231 | -57 | -25 | -599 |
| Profit before tax | 806 | 1.394 | 2.124 | 2.459 | 4.154 | 3.068 | 1.461 | 814 | 566 | 586 | 6 | 596 | 2.637 |
| Tax | 203 | 347 | 533 | 585 | 948 | 572 | 323 | 181 | 163 | 127 | 1 | 132 | 585 |
| Net profit | 602 | 1.048 | 1.591 | 1.873 | 3.206 | 2.497 | 1.138 | 633 | 404 | 459 | 5 | 465 | 2.052 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 10.750 | 14.197 | 16.259 | 12.774 | 17.513 | 15.382 | 17.669 | 17.890 | 15.145 | 15.203 | 11.413 | 13.884 | 18.010 |
| Equity | — | 11.784 | 12.875 | 8.748 | 10.254 | 10.250 | 10.388 | 10.022 | 9.925 | 6.384 | 5.939 | 6.404 | 5.455 |
| Long-term debt | 2.836 | 1.321 | 1.227 | 1.138 | 1.043 | 948 | 855 | 760 | 665 | 570 | 474 | 379 | 0 |
| Short-term debt | 1.372 | 941 | 2.157 | 2.888 | 6.216 | 4.183 | 6.425 | 7.106 | 4.555 | 8.249 | 4.997 | 7.076 | 12.555 |
| Total debt | 4.208 | 2.262 | 3.385 | 4.026 | 7.259 | 5.131 | 7.280 | 7.866 | 5.220 | 8.819 | 5.471 | 7.455 | 12.555 |
EBITDA margin
56.9%
This company
15.8%
Market median
+260% vs market
20122024
Equity ratio
30.3%
This company
38.2%
Market median
+21% vs market
20122024
Return on equity
37.6%
This company
18.4%
Market median
+104% vs market
20122024
Net profit margin
33.2%
This company
8.1%
Market median
+310% vs market
20122024
Asset turnover
0.34×
This company
1.12×
Market median
-70% vs market
20122024
Debt / equity
2.30×
This company
0.62×
Market median
-271% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LK Management | Management | 2010 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2010 | — | — | |
| Board of Directors | 2010 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2010 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
LKJ HOLDING 2010 ApS | Company | 50.0% | 50.0% | 2024 |
CE-PHARMAMACHINERY ApS | Company | 33.3% | 33.3% | 2024 |
Familien Kjeldsen Holding ApS | Company | 15.0% | 15.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LKJ HOLDING 2010 ApS
LEKAPHARM A/S Board members of LEKAPHARM A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lasse Kjeldsen | Management | 0 companies |
| Jacob Penney Kjeldsen | Board of Directors | 0 companies |
| Claus Skærsholm Kjeldsen | Board of Directors | 0 companies |
| Emil Bødker Kjeldsen | Board of Directors | 0 companies |
| Susanne Frederiksen | Chairman | 0 companies |